Lars Bastholt
Auto-generated profile, based on publicly available information

Lars Bastholt

Department of Oncology, Odense University Hospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JLJames Larkin
James Larkin
VCVanna na Chiarion-Sileni
Vanna na Chiarion-Sileni
RGRene Gonzalez
Rene Gonzalez
JGJean Jacques Grob
Jean Jacques Grob
CCC. Lance Cowey
C. Lance Cowey
JWJedd D. Wolchok
Jedd D. Wolchok
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma. We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here. The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1–negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group. Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1–negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.)

17 October 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
JLJames Larkin
James Larkin
VCVanna na Chiarion-Sileni
Vanna na Chiarion-Sileni
RGRene Gonzalez
Rene Gonzalez
JGJean-Jacques Grob
Jean-Jacques Grob
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
JWJedd D. Wolchok
Jedd D. Wolchok
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.

15 January 2020 in Nature
Verified
Journal Article
Closed access
PDF file
RCRita Cabrita
Rita Cabrita
MLMartin Lauss
Martin Lauss
Adriana SannaAdriana Sanna
Adriana Sanna
Marco DoniaMarco Donia
Marco Donia
MLMathilde Skaarup Larsen
Mathilde Skaarup Larsen
Göran JönssonGöran Jönsson
Göran Jönsson

1 July 2014 in The Lancet
Verified
Journal Article
Closed access
MBMarcia S Brose
Marcia S Brose
CNChristopher M Nutting
Christopher M Nutting
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
RERosella Elisei
Rosella Elisei
SSSalvatore Siena
Salvatore Siena
MSMartin J Schlumberger
Martin J Schlumberger

10 November 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AEAlexander M.M. Eggermont
Alexander M.M. Eggermont
VCVanna na Chiarion-Sileni
Vanna na Chiarion-Sileni
JGJean-Jacques Grob
Jean-Jacques Grob
RDReinhard Dummer
Reinhard Dummer
JWJedd D. Wolchok
Jedd D. Wolchok
alessandro testorialessandro testori
alessandro testori
On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resection of stage III melanoma. After patients had undergone complete resection of stage III cutaneous melanoma, we randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placebo (476) every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred. Recurrence-free survival was the primary end point. Secondary end points included overall survival, distant metastasis–free survival, and safety. At a median follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 40.8% in the ipilimumab group, as compared with 30.3% in the placebo group (hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). The rate of overall survival at 5 years was 65.4% in the ipilimumab group, as compared with 54.4% in the placebo group (hazard ratio for death, 0.72; 95.1% CI, 0.58 to 0.88; P=0.001). The rate of distant metastasis–free survival at 5 years was 48.3% in the ipilimumab group, as compared with 38.9% in the placebo group (hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P=0.002). Adverse events of grade 3 or 4 occurred in 54.1% of the patients in the ipilimumab group and in 26.2% of those in the placebo group. Immune-related adverse events of grade 3 or 4 occurred in 41.6% of the patients in the ipilimumab group and in 2.7% of those in the placebo group. In the ipilimumab group, 5 patients (1.1%) died owing to immune-related adverse events. As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis–free survival than placebo. There were more immune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00636168, and EudraCT number, 2007-001974-10.)

1 September 2003 in The Lancet
Verified
Journal Article
Closed access
JOJens Overgaard
Jens Overgaard
HHHanne Sand Hansen
Hanne Sand Hansen
LSLena Specht
Lena Specht
MOMarie Overgaard
Marie Overgaard
CGCai Grau
Cai Grau
JEJan F Evensen
Jan F Evensen